Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 754 clinical trials
None
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

kidney biopsy
body mass index
lupus
corticosteroids
chloroquine
  • 261 views
  • 30 Sep, 2021
  • 98 locations
None
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

calcium
phosphodiesterase v inhibitor
rheumatism
raynaud's syndrome
myositis
  • 0 views
  • 12 Aug, 2021
  • 10 locations
None
Study of M5049 in CLE and SLE Participants

This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).

cutaneous lupus
lupus
  • 0 views
  • 24 Nov, 2021
  • 13 locations
None
A Study In Adults With Moderate To Severe Dermatomyositis

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

dermatomyositis
experimental drug
rash
corticosteroids
  • 134 views
  • 17 Nov, 2021
  • 55 locations
None
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder …

rash
a 10
myopathy
corticosteroids
dermatomyositis
  • 35 views
  • 14 Jun, 2021
  • 103 locations
None
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)

The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States, Mexico, Australia, France, Spain, and the United Kingdom. The objectives of SPIN are (1) to assemble a large cohort of SSc patients …

raynaud's syndrome
skin care
rheumatism
scleroderma
  • 0 views
  • 26 Oct, 2021
  • 1 location
None
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

anifrolumab
lupus
  • 0 views
  • 31 Oct, 2021
  • 98 locations
None
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

cutaneous lupus
autoantibody test
glucocorticoids
lupus
  • 0 views
  • 28 Nov, 2021
  • 82 locations
None
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sj gren's Syndrome or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjgren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).

abatacept
sjogren's syndrome
arthritis
lupus
progressive systemic sclerosis
  • 330 views
  • 28 Nov, 2021
  • 1 location
None
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

HSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries. However, data and specific guidelines on the best timing of HSCT in the course of dcSSc are lacking. In particular, …

  • 0 views
  • 18 Apr, 2021
  • 14 locations